Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 4  |  Page : 799-804

The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: A literature review


Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Correspondence Address:
Dingzhi Huang
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.146054

Rights and Permissions

The presence of a systemic inflammatory response (SIR) is recognized to occur in the presence of malignancy. And the SIR-Glasgow Prognostic Score (GPS)/modified GPS (mGPS) composed of the C-reactive protein (CRP) and albumin is a tumor stage- and treatment-independent, routinely available and well-standardized prognostic factor, reflects both an ongoing SIR (CRP) and a progressive nutritional decline (albumin) in patients with advanced cancer. Previous studies showed that GPS/mGPS appear to be a superior prognostic factor compared with other cellular components of the SIR and Eastern Cooperative Oncology Group performance status in some aspects. Besides, GPS/mGPS aids at deciding active or palliation treatment and selecting patients with gastric cancer who tolerate platinum-based chemotherapy. Therefore, GPS/mGPS may be incorporated or combined with other factors to improve assessment of prognosis and guide treatment of patients with gastric cancer in a routine clinical work. However, it remains to be determined whether the GPS and mGPS have different prognostic value in each stage of gastric cancer and the necessity of normalization of the GPS/mGPS by anti-inflammation and maintenance of performance status or nutritional status in clinical work.

Abstract in Chinese

在胃癌患者中系统性以炎症为基础的格拉斯哥预后评分的价值: 文献综述 摘要 全身性炎症反应(SIR)被公认为在恶性肿瘤的出现时发生。并且,在中晚期癌症患者中,由C反应蛋白(CRP)和白蛋白组成的SIR-格拉斯哥预后评分(GPS)/改良GPS(mGPS)是肿瘤分期和治疗不相关的,常规可用的和规范的预后因素,反映了一个持续的全身性炎症反应(SIR)/(CRP)和一个渐进的营养(白蛋白)下降过程。以往的研究表明,GPS /mGPS较其它细胞成分的SIR,表现为一个更好的预后因素,东部肿瘤协作组在一些方面也表现出其地位。此外,GPS /mGPS可以帮助决定或积极治疗还是保守治疗,选择可耐受铂类为基础的化疗的胃癌患者。因此,GPS / mGPS可以结合其他因素来提高在日常临床工作中胃癌患者的预后和指导治疗的评价。然而,在临床工作中,有待确定是,GPS/mGPS在胃癌的各个阶段是否有不同的预后值,以及通过抗炎和表现状态或营养状况维持的GPS /mGPS是否需要标准化。 关键词:胃癌,格拉斯哥预后评分,改良的格拉斯哥预后评分,预后值



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4019    
    Printed141    
    Emailed0    
    PDF Downloaded249    
    Comments [Add]    

Recommend this journal